Damora Therapeutics, Inc. Ordinary Shares
DMRA
21 hedge funds and large institutions have $3.92M invested in Damora Therapeutics, Inc. Ordinary Shares in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 9 closing their positions.
1,300% more call options, than puts
Call options by funds: $14K | Put options by funds: $1K
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
0.79% less ownership
Funds ownership: 1.59% → 0.8% (-0.79%)
22% less funds holding
Funds holding: 27 → 21 (-6)
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
85% less capital invested
Capital invested by funds: $25.7M → $3.92M (-$21.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$112K |
| 2 |
Renaissance Technologies
New York
|
+$61.6K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$27.2K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$23K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$11.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$4.57M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.57M |
| 3 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$618K |
| 4 |
BlackRock
New York
|
-$347K |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$252K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$242K | -3,837 | Closed |
|
27
Two Sigma Advisers
New York
| – | -$123K | -1,956 | Closed |
|
|
TCOT
28
Trust Company of Toledo
Holland,
Ohio
| – | -$56.5K | -897 | Closed |
|
29
Belvedere Trading
Chicago,
Illinois
| – | -$37.9K | -601 | Closed |
|
30
Two Sigma Investments
New York
| – | -$32.1K | -509 | Closed |
|
31
Citadel Advisors
Miami,
Florida
| – | -$5.64K | -89 | Closed |
|
DMRA Hedge Fund Activity: Q3 2023 in Review
21 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) for Q3 2023, worth a combined $3.92M — down 85% from $25.7M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of DMRA and 3 opened new positions — a net loss of 6 holders — while 6 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $112K. The largest seller was OrbiMed, cutting an estimated $4.57M.
- 21 institutional investors held Damora Therapeutics, Inc. Ordinary Shares (DMRA) as of Q3 2023, down from 27 in Q2 2023.
- Funds reported $3.92M of Damora Therapeutics, Inc. Ordinary Shares stock for Q3 2023, down 85% quarter-over-quarter.
- 3 funds opened new Damora Therapeutics, Inc. Ordinary Shares positions in Q3 2023 and 9 closed out, a net change of -6 holders.
- The largest Damora Therapeutics, Inc. Ordinary Shares buyer in Q3 2023 was Vanguard Group, an estimated $112K added.
- The largest Damora Therapeutics, Inc. Ordinary Shares seller in Q3 2023 was OrbiMed, an estimated $4.57M sold.
Based on aggregated 13F filings for Q3 2023.